- Patients must have platinum-sensitive or platinum-resistant recurrent or persistent or refractory high grade serous epithelial ovarian, fallopian tube, or primary peritoneal carcinoma AND carry a germline and/or somatic mutation in BRCA1 or BRCA2 (confirmation required via genetic test report)